HOME > LATEST
LATEST
-
REGULATORY Japan Govt OKs Economic Package to Counter US Tariff Impact
April 28, 2025
-
BUSINESS Sanofi’s Dupixent Filed for Bullous Pemphigoid in Japan
April 28, 2025
-
REGULATORY ASKA’s Contraceptive, Vabysmo Label Expansion Now in Line for Japan Approval
April 28, 2025
-
BUSINESS Seikagaku, Ono to Tie Up on Osteoarthritis Drug in Japan
April 28, 2025
-
REGULATORY MHLW/PMDA, FDA Philippines to Boost Regulatory Cooperation
April 28, 2025
-
COLUMN The Evolution of HR: From BP to Agile
April 28, 2025
-
REGULATORY LDP Members Raise No Call for Tax Cuts, Fret Inflationary Impact on Medical Facilities: Fiscal Reform HQ
April 25, 2025
-
BUSINESS BMS Oncology VP Goto to Lead Argenx Japan
April 25, 2025
-
BUSINESS Gilead Files Trodelvy for HR+/HER2- Breast Cancer in Japan
April 25, 2025
-
REGULATORY Japan to Buttress Regulatory Communication Efforts for Drug Originators Overseas
April 25, 2025
-
BUSINESS Enhertu Filed for HER2 Positive Solid Tumors in Japan
April 25, 2025
-
BUSINESS Sanofi Looks to Join Top 3 in Japan Pharma Market by 2030
April 25, 2025
-
BUSINESS Meiji’s Rezurock Grabs Approval in Taiwan
April 25, 2025
-
REGULATORY “Time to Revise” Fee Premiums for Generic Use: Chuikyo Payer Rep
April 25, 2025
-
REGULATORY LDP Group Calls for Keeping Health Coverage for Pain Relief Patches
April 25, 2025
-
BUSINESS Novo Unveils 4 Billion Yen Investment in Japan Factory
April 24, 2025
-
ORGANIZATION US Tariffs Would Hinder Access to Innovative Drugs: JPMA President
April 24, 2025
-
REGULATORY MHLW to Present Estimate on Coverage Removal of OTC-Like Meds at 3-Party Talks
April 24, 2025
-
REGULATORY MOF’s Spring Debate Puts Special Focus on CEA, More Aggressive Re-Pricing Eyed
April 24, 2025
-
BUSINESS Japan Approves Spikevax’s Prefilled Syringe Version
April 24, 2025
ページ
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…